ECSP17023281A - Inhibidores de mk2 y sus usos - Google Patents
Inhibidores de mk2 y sus usosInfo
- Publication number
- ECSP17023281A ECSP17023281A ECIEPI201723281A ECPI201723281A ECSP17023281A EC SP17023281 A ECSP17023281 A EC SP17023281A EC IEPI201723281 A ECIEPI201723281 A EC IEPI201723281A EC PI201723281 A ECPI201723281 A EC PI201723281A EC SP17023281 A ECSP17023281 A EC SP17023281A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- compositions
- methods
- present
- provides compounds
- Prior art date
Links
- 229940124789 MK2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención proporciona compuestos, composiciones de los mismos y métodos para utilizarlos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051788P | 2014-09-17 | 2014-09-17 | |
| US201562199927P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17023281A true ECSP17023281A (es) | 2017-06-30 |
Family
ID=55454109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201723281A ECSP17023281A (es) | 2014-09-17 | 2017-04-13 | Inhibidores de mk2 y sus usos |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9458175B2 (es) |
| EP (2) | EP3912981A1 (es) |
| JP (3) | JP6556225B2 (es) |
| KR (1) | KR102457848B1 (es) |
| CN (1) | CN106998692B (es) |
| AU (1) | AU2015317741B2 (es) |
| BR (1) | BR112017005266B1 (es) |
| CA (1) | CA2961607C (es) |
| CL (1) | CL2017000576A1 (es) |
| CO (1) | CO2017003279A2 (es) |
| CY (1) | CY1124215T1 (es) |
| DK (1) | DK3193611T3 (es) |
| EA (1) | EA037299B1 (es) |
| EC (1) | ECSP17023281A (es) |
| ES (1) | ES2874561T3 (es) |
| HR (1) | HRP20210529T1 (es) |
| HU (1) | HUE054347T2 (es) |
| IL (1) | IL251051B (es) |
| LT (1) | LT3193611T (es) |
| MA (1) | MA40534B1 (es) |
| MX (2) | MX2017003359A (es) |
| PL (1) | PL3193611T3 (es) |
| PT (1) | PT3193611T (es) |
| RS (1) | RS62017B1 (es) |
| SA (1) | SA517381115B1 (es) |
| SG (2) | SG10201902326XA (es) |
| SI (1) | SI3193611T1 (es) |
| SM (1) | SMT202100311T1 (es) |
| TW (1) | TWI744217B (es) |
| WO (1) | WO2016044463A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| MA40534B1 (fr) | 2014-09-17 | 2021-04-30 | Celgene Car Llc | Inhibiteurs de mk2 et leurs utilisations |
| CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
| WO2018170201A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| CN110678178B (zh) * | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| JP7282039B2 (ja) | 2017-03-16 | 2023-05-26 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体 |
| JP7200120B2 (ja) * | 2017-03-16 | 2023-01-06 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤として有用なヘテロアリール化合物 |
| WO2018170204A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
| CN107058259A (zh) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | 分子标志物mk2基因及其应用 |
| US20220251105A1 (en) * | 2019-05-17 | 2022-08-11 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| CA3171335A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Mono and combination therapies with ulk1/2 inhibitors |
| EP4114411A4 (en) * | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| EP4185382A4 (en) * | 2020-07-24 | 2024-09-04 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| WO2022104097A2 (en) * | 2020-11-12 | 2022-05-19 | Akttyva Therapeutics, Inc. | Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders |
| TW202246282A (zh) | 2021-02-01 | 2022-12-01 | 美商西建公司 | Ｍｋ２抑制劑、其合成及其中間體 |
| EP4079855A1 (en) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound and method for the prophylaxis and treatment of leukemia |
| TW202328141A (zh) * | 2021-08-27 | 2023-07-16 | 大陸商瑞石生物醫藥有限公司 | 喹啉并呋喃衍生物及其用途 |
| EP4464694A1 (en) | 2022-01-14 | 2024-11-20 | Shanghai Hansoh Biomedical Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
| WO2024044731A1 (en) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| TW202432106A (zh) * | 2022-10-27 | 2024-08-16 | 美商必治妥美雅史谷比公司 | Mk2抑制劑及其用途 |
| WO2024167950A1 (en) * | 2023-02-07 | 2024-08-15 | Celgene Corporation | Compounds and compositions useful as degraders of mk2 kinase |
| WO2025002076A1 (zh) * | 2023-06-26 | 2025-01-02 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
| BR9507200A (pt) | 1994-03-25 | 1997-09-16 | Isotechnika Inc | Melhora da eficácia de drogas por deuteração |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| CA2510298A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| MX2007009388A (es) | 2005-02-04 | 2007-09-25 | Senomyx Inc | Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles. |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| JP2010505961A (ja) | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| CA2693904A1 (en) | 2007-07-16 | 2009-01-22 | Novartis Ag | Heterocyclic compounds useful as mk2 inhibitors |
| US8907095B2 (en) | 2007-10-22 | 2014-12-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CN108047142B (zh) | 2008-06-27 | 2021-08-03 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| ES2742261T3 (es) * | 2011-04-15 | 2020-02-13 | Hivih | Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos |
| CN112029513B (zh) | 2012-02-22 | 2024-02-23 | 默克专利股份有限公司 | 液晶介质 |
| JPWO2013146963A1 (ja) * | 2012-03-28 | 2015-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| KR20150105292A (ko) * | 2012-09-24 | 2015-09-16 | 클레어몬트 스피드 | 모바일 송신기 제어형 데이터 액세스 및 데이터 삭제 방법 및 시스템 |
| WO2014050779A1 (ja) * | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| WO2015050957A2 (en) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Treatments for systemic lupus erythematosus |
| WO2016032882A1 (en) | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| MA40534B1 (fr) | 2014-09-17 | 2021-04-30 | Celgene Car Llc | Inhibiteurs de mk2 et leurs utilisations |
| US10087225B2 (en) | 2015-01-08 | 2018-10-02 | Moerae Matrix, Inc. | Formulation of MK2 inhibitor peptides |
| WO2018170204A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
| WO2018170201A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| JP7200120B2 (ja) | 2017-03-16 | 2023-01-06 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤として有用なヘテロアリール化合物 |
| JP7282039B2 (ja) | 2017-03-16 | 2023-05-26 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体 |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| US20220251105A1 (en) | 2019-05-17 | 2022-08-11 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| EP4185382A4 (en) | 2020-07-24 | 2024-09-04 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
-
2015
- 2015-09-16 MA MA40534A patent/MA40534B1/fr unknown
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/ja active Active
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
- 2015-09-16 TW TW104130645A patent/TWI744217B/zh active
- 2015-09-16 PL PL15842903T patent/PL3193611T3/pl unknown
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/en active Pending
- 2015-09-16 MX MX2017003359A patent/MX2017003359A/es active IP Right Grant
- 2015-09-16 EA EA201790380A patent/EA037299B1/ru not_active IP Right Cessation
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/lt unknown
- 2015-09-16 CA CA2961607A patent/CA2961607C/en active Active
- 2015-09-16 RS RS20210725A patent/RS62017B1/sr unknown
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/da active
- 2015-09-16 PT PT158429035T patent/PT3193611T/pt unknown
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/en active Application Filing
- 2015-09-16 SM SM20210311T patent/SMT202100311T1/it unknown
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 SI SI201531617T patent/SI3193611T1/sl unknown
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/zh active Active
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/ko active IP Right Grant
- 2015-09-16 ES ES15842903T patent/ES2874561T3/es active Active
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/en active Active
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/hu unknown
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/pt active IP Right Grant
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/es unknown
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/es unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/ar unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/es unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/es unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/ja active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-03-31 HR HRP20210529TT patent/HRP20210529T1/hr unknown
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/el unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17023281A (es) | Inhibidores de mk2 y sus usos | |
| CO2018005381A2 (es) | Inhibidores éster de acc y usos de los mismos | |
| MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
| ECSP18008905A (es) | Tricíclicos sustituidos y método para usarlos. | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| UY37523A (es) | Anticuerpos anti-ox40 y sus usos | |
| IL248519A0 (en) | Bioceramic compositions and biomodulatory uses thereof | |
| ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t |